All News

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.

I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC.

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.

Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.

As a cancer survivor I explain the importance of looking forward to life.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.

Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC.

Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC.

Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes.

Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.

There are many instances where teddy bears can be the key to opening hearts and minds during cancer care.

The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.

Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models.

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.

Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer.

A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.

Christine Simonelli, B.S.N., RN, CCRC, OCN, is amazing, and goes out of her way to help patients and providers.

I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease myself.